{"id":"NCT01400932","sponsor":"GlaxoSmithKline","briefTitle":"Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects","officialTitle":"Study STF115288, a Clinical Confirmation Study of GI148512 (Benzoyl Peroxide 3% Gel) in the Treatment of Acne Vulgaris in Japanese Subjects.- A Multicenter, Randomized, Double-blinded, Vehicle-controlled, Parallel-group Study -","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2012-04","completion":"2012-04","firstPosted":"2011-07-25","resultsPosted":"2014-08-05","lastUpdate":"2014-08-05"},"enrollment":360,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"GI148512","otherNames":["Benzoyl Peroxide 3% Gel"]},{"type":"DRUG","name":"vehicle gel","otherNames":[]}],"arms":[{"label":"GI148512 (Benzoyl Peroxide 3% Gel)","type":"EXPERIMENTAL"},{"label":"vehicle gel","type":"PLACEBO_COMPARATOR"}],"summary":"This is a multicenter, randomized, double-blinded, vehicle-controlled, parallel-group study in Japanese subjects with acne vulgaris to demonstrate the efficacy of GI148512 (benzoyl peroxide \\[BPO\\] 3% gel) when applied once daily for 12 weeks. This study will also evaluate the safety of GI148512 when applied topically once daily for 12 weeks.","primaryOutcome":{"measure":"Absolute Change in Total Lesion Counts From Baseline to Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"GI148512","deltaMin":-42.9,"sd":1.93},{"arm":"Vehicle Gel","deltaMin":-22,"sd":1.89}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":15},"locations":{"siteCount":19,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":178},"commonTop":["Nasopharyngitis","Dry skin","Facial pain","Dermatitis contact","Pruritus"]}}